Xarelto Lawyer

Xarelto (also known as rivaroxaban), was released in the US in July 2011 by Johnson & Johnson’s pharmaceutical division Janssen. Manufactured by the German conglomerate Bayer, it is one of several blood thinning agents similar to Coumadin (also known as Warfarin) to treat blood clots.

It was developed by Bayer for patients who are at high risk for pulmonary embolisms (chest pain, shortness of breath and – in extreme instances – coughing up blood) and who exhibit symptoms of deep vein thrombosis: pain, redness, warmness and/or swelling in the lower legs.

If you have suffered an injury or illness as a result of taking Xarelto and you feel you were not properly warned of the potentially serious side effects, you should consult with a Xarelto lawyer. Call our attorneys today.Xarelto Lawyer - Price Benowitz LLP

Xarelto Side Effects and Risks

Xarelto was approved by the US Food and Drug Administration (FDA) to reduce blood clot risks in patients after they underwent certain types of surgeries, such as knee or hip replacements. The drug was approved via a fast-track regulatory review for the general treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Like Pradaxa – another alternative to Warfarin which has also received FDA scrutiny over growing concerns of risks — a significant number of patients have experienced serious side effects including, but not necessarily limited to:

  • Undue or extraordinary bleeding and bruising
  • Unusually heavy menstrual periods
  • General weakness, lightheadedness, and/or dizziness
  • Profound headaches
  • Oddly-colored urine (from very dark yellow to pink)
  • Blood in the stool
  • Coughing up blood
  • Tingling or numbness in the legs and feet
  • Difficulty in moving legs or feet
  • Death due to uncontrollable bleeding and/or hemorrhaging from the brain, rectum or intestines primarily brain, rectal, or intestinal hemorrhaging

FDA Warnings and Concerning Data 

A March 2014 FDA Adverse Event Reporting found the optimal timing between the administration of Xarelto and neuraxial procedures is not known. The update refers to ways to reduce the potential risk of bleeding associated with the concurrent use of Xarelto, or Rivaroxaban, and epidurals, or spinal anesthesia/analgesia or spinal puncture.

If the doctor chooses to administer anticoagulation drugs in the context of an epidural, or spinal anesthesia/analgesia or lumbar puncture, they should monitor the patient’s condition frequently to detect signs or symptoms of neurological impairment (i.e. midline back pain, sensory and motor deficits, and numbness, tingling or weakness in lower limbs), bowel and/or bladder dysfunction, and spinal hematoma. Physicians should instruct patients to immediately report if they experience any of these signs or symptoms or other serious side effects.

Due to the deaths and serious injuries linked to medications similar to Xarelto, and the shared chemical compounds between those drugs and Xarelto, doctors have reportedly begun to use Xarelto more sparingly. The FDA has received data on Xarelto from several neutral clinical trials and regularly publishes safety bulletins dedicated to developments with use of the drug.

The Institute for Safe Medication Practices cited concerns about the safety of Xarelto in its May 2014 QuarterWatch report: “In the latest data we detected a new trend in the numerous serious adverse event reports associated with two newer anticoagulant drugs: dabigatran (PRADAXA) and rivaroxaban (XARELTO).

Cases for rivaroxaban (n=680) were steadily increasing and now outnumbered those of dabigatran (n=528), the drug that had been the main focus of safety concerns in QuarterWatch and elsewhere. The trends were mostly explained by a major change in the number of patients exposed to the two drugs.

Total dispensed outpatient prescriptions for rivaroxaban have rapidly increased to nearly 1 million prescriptions per quarter, while dabigatran utilization has steadily declined since a peak in early 2012. By the end of 2013, rivaroxaban prescriptions outnumbered dabigatran by almost 2 to 1, according to data from IMS Health, Inc.”

Xarelto Lawsuits Have Been Filed

Pradaxa has been prescribed in the US longer than Xarelto and, as such, a greater number of Pradaxa lawsuits have stacked up. However, since the two drugs are different brands of the same compound – and patients are experiencing similar negative side effects — Xarelto lawsuits are now gaining momentum.

Injured plaintiffs who have filed defective drug lawsuits against the manufacturers of blood thinners allege that the manufacturers failed to adequately warn patients and doctors of known hazardous side effects and produced defective and dangerous products.

Like Pradaxa, Xarelto – if not properly administered due to lack of clear instructions for physicians and patients — can and has triggered internal bleeding resulting in serious injuries and fatalities. Many US doctors have expressed concerns, both in media reports and in medical reviews, about the lack of information regarding the risks that Xarelto may pose. You can read more about that here.

The makers of Xarelto have since included a boxed warning on the potentially lethal side effects associated with developing blood clots and internal bleeding. You can read the full warning here.

If you are experiencing serious complications or side effects from Xarelto, such as internal bleeding, or you have lost a family member who was taking the drug, you should consult with an experienced Xarelto lawyer. You will want to talk to an attorney who has pursued claims against pharmaceutical companies for dangerous or defective drugs to determine if your case is likely to result in a successful civil claim.

Damages can include associated medical expenses, lost wages, pain and suffering, and – in some cases — punitive damages. Wrongful death actions can be brought by certain primary beneficiaries of the decedent, such as a spouse, parent or child. In certain jurisdictions, if none of the primary beneficiaries are living, secondary beneficiaries may be eligible to pursue a claim.

The secondary beneficiaries are relatives by either blood or marriage who were substantially dependent upon the decedent. Speak to an attorney to find out if you are eligible to bring a lawsuit on behalf of your loved one, including survivor actions and wrongful death claims.

Statute of Limitations in Xarelto Lawsuits

The statutes of limitations in various districts may differ, but the concept remains the same in that there is generally a limited time for you to bring a claim if you were hurt, or you suffered the loss of a loved one, due to a defective or dangerous product.

Generally speaking, those who file claims in Maryland and the District of Columbia have three years from the time the injured party knows, or should have known, of the injury, its probably cause, and either the manufacturer’s wrongdoing or product defect. Injury claims filed in Virginia are capped at two years.

Exceptions to these time limits may apply, but you will need to speak with a dedicated attorney to determine if that is the case for your claim.